Holocene Advisors’s Teva Pharmaceutical Industries TEVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-166,867
Closed -$5.65M – 966
2026
Q2
$5.65M Sell
166,867
-13,982
-8% -$466K 0.01% 395
2026
Q1
$5.45M Buy
+180,849
New +$5.82M 0.01% 388
2025
Q3
– Sell
-3,053,340
Closed -$51.2M – 911
2025
Q2
$51.2M Sell
3,053,340
-967,288
-24% -$15.6M 0.12% 168
2025
Q1
$61.8M Buy
4,020,628
+851,215
+27% +$15.2M 0.18% 151
2024
Q4
$69.9M Buy
3,169,413
+957,330
+43% +$17.4M 0.22% 133
2024
Q3
$39.9M Sell
2,212,083
-2,374,189
-52% -$41.6M 0.16% 170
2024
Q2
$74.5M Sell
4,586,272
-376,184
-8% -$5.79M 0.31% 97
2024
Q1
$70M Sell
4,962,456
-295,739
-6% -$3.73M 0.26% 126
2023
Q4
$54.9M Buy
5,258,195
+135,422
+3% +$1.26M 0.21% 142
2023
Q3
$52.3M Buy
+5,122,773
New +$47.7M 0.23% 136

Other funds holding TEVA

Holocene Advisors's TEVA Position: Q3 2026 in Review

Holocene Advisors sold out of Teva Pharmaceutical Industries (TEVA) in Q3 2026, closing a stake of 166,867 shares — an estimated $5.65M sold.

Holocene Advisors first reported a position in TEVA in Q3 2023 and held it in 10 quarters. The position peaked at $74.5M in Q2 2024. 600 funds tracked by Wall St. Rank hold TEVA as of Q3 2026.

  • Holocene Advisors reported no remaining Teva Pharmaceutical Industries position as of Q3 2026 after selling out during the quarter.
  • Holocene Advisors sold 166,867 Teva Pharmaceutical Industries shares in Q3 2026, an estimated $5.65M.
  • Holocene Advisors first reported a position in Teva Pharmaceutical Industries in Q3 2023 and held it in 10 quarters.
  • Holocene Advisors's Teva Pharmaceutical Industries position peaked at $74.5M in Q2 2024.
  • 600 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries as of Q3 2026.

Based on Holocene Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.